Bristol-Myers Squibb Co
1BMY
Company Profile
Business description
Bristol-Myers Squibb discovers, develops, and markets drugs for various therapeutic areas, such as cardiovascular, cancer, and immune disorders. A key focus for Bristol is immuno-oncology, where the firm is a leader in drug development. Bristol derives close to 70% of total sales from the US, showing a higher dependence on the US market than most of its peer group.
Contact
Route 206 and Province Line Road
Princeton
New JerseyNJ08543
USAT: +1 609 252-4621
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
34,100
Stocks News & Analysis
stocks
Has the most hated company on the ASX 200 bounced back?
Encouraging results indicate a potential turnaround story.
stocks
Amazon earnings: Good results, with AWS still a winner; fear on profitability guidance is overblown
We think Amazon stock looks attractive.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,922.00 | 77.00 | -0.86% |
| CAC 40 | 7,618.30 | 72.14 | 0.96% |
| DAX 40 | 23,741.61 | 315.64 | 1.35% |
| Dow JONES (US) | 43,920.62 | 210.36 | -0.48% |
| FTSE 100 | 9,099.34 | 33.47 | -0.37% |
| HKSE | 24,733.45 | 39.88 | -0.16% |
| NASDAQ | 20,904.37 | 254.24 | 1.23% |
| Nikkei 225 | 40,290.70 | 779.12 | -1.90% |
| NZX 50 Index | 12,684.04 | 139.70 | -1.09% |
| S&P 500 | 6,293.25 | 55.24 | 0.89% |
| S&P/ASX 200 | 8,663.70 | 79.10 | -0.90% |
| SSE Composite Index | 3,583.31 | 23.36 | 0.66% |